Next 10 |
home / stock / fgen / fgen articles
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced it will host the second part of its virtual KOL in...
FibroGen Inc (NASDAQ:FGEN) shares initially traded higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND)...
Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter ...
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that Thane Wettig, Chief Executive Officer, will p...
Shares of Beyond, Inc. (NYSE:BYON) fell sharply during Tuesday’s session following weaker-than-expected quarterly results. Beyond posted adj...
FibroGen, Inc. (NASDAQ:FGEN) shares are trading higher Tuesday after the company posted mixed first-quarter financial results. Here's a look a...
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday. Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply d...
Shares of Zeta Global Holdings Corp. (NASDAQ:ZETA) rose sharply in today's pre-market trading after the company reported better-than-expected ...
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce first quarter 2024 financial results on Monday, May...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...